Urogen Pharma Ltd. (URGN) Reaches $49.70 After 5.00% Up Move; Entellus Medical (ENTL) SI Decreased By 3.59%

February 20, 2018 - By Richard Conner

The stock of Urogen Pharma Ltd. (NASDAQ:URGN) is a huge mover today! The stock increased 3.71% or $1.78 during the last trading session, reaching $49.7. About 116,021 shares traded. Urogen Pharma Ltd. (NASDAQ:URGN) has 0.00% since February 20, 2017 and is . It has underperformed by 16.70% the S&P500.The move comes after 5 months positive chart setup for the $756.18M company. It was reported on Feb, 20 by Barchart.com. We have $52.19 PT which if reached, will make NASDAQ:URGN worth $37.81 million more.

Entellus Medical Incorporated (NASDAQ:ENTL) had a decrease of 3.59% in short interest. ENTL’s SI was 2.23M shares in February as released by FINRA. Its down 3.59% from 2.32 million shares previously. With 114,400 avg volume, 20 days are for Entellus Medical Incorporated (NASDAQ:ENTL)’s short sellers to cover ENTL’s short positions. The SI to Entellus Medical Incorporated’s float is 24.7%. The stock decreased 0.08% or $0.02 during the last trading session, reaching $24.04. About 19,996 shares traded. Entellus Medical, Inc. (NASDAQ:ENTL) has declined 17.59% since February 20, 2017 and is downtrending. It has underperformed by 34.29% the S&P500.

UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing therapies for urological pathologies. The company has market cap of $756.18 million. The Company’s lead product candidates, MitoGel and VesiGel are formulations of the chemotherapy drug Mitomycin C, a generic drug which is currently used off-label for urothelial cancer treatment only in a water formulation as an adjuvant, or supplemental post-surgery, therapy. It has a 214.22 P/E ratio. The firm is developing its product candidates as chemoablation agents, which are designed to remove tumors by non-surgical means, to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma, and low-grade bladder cancer.

Analysts await Urogen Pharma Ltd. (NASDAQ:URGN) to report earnings on May, 4. After $-0.02 actual EPS reported by Urogen Pharma Ltd. for the previous quarter, Wall Street now forecasts 3,300.00% negative EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: